UBS/CALL/ELI LILLY & CO/750.001/0.01/21.06.24 | Market Closed - Swiss Exchange 08:50:00 23/05/2024 pm IST | ||
| 0.64 CHF | +10.34% |
|
| Current month | +39.13% | ||
| 1 month | +77.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 0.64 | +10.34% |
| 22/24/22 | 0.58 | -6.45% |
| 21/24/21 | 0.62 | +63.16% |
| 17/24/17 | 0.38 | -20.83% |
| 16/24/16 | 0.48 | +14.29% |
Delayed Quote Swiss Exchange
Last update May 23, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYENU | |
| ISIN | CH1299193313 |
| Date issued | 16/10/2023 |
| Strike | 750 $ |
| Maturity | 21/06/2024 (29 Days) |
| Parity | 100 : 1 |
| Emission price | 0.22 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.78 CHF |
|---|---|
| Lowest since issue | 0.1 CHF |
| Spread | 0.06 CHF |
| Spread % | 8.57% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- LLYENU Warrant
